HUP0302492A2 - Gyógyszer megszokás megelőzésére alkalmas eljárások és készítmények - Google Patents

Gyógyszer megszokás megelőzésére alkalmas eljárások és készítmények

Info

Publication number
HUP0302492A2
HUP0302492A2 HU0302492A HUP0302492A HUP0302492A2 HU P0302492 A2 HUP0302492 A2 HU P0302492A2 HU 0302492 A HU0302492 A HU 0302492A HU P0302492 A HUP0302492 A HU P0302492A HU P0302492 A2 HUP0302492 A2 HU P0302492A2
Authority
HU
Hungary
Prior art keywords
prevention
methods
medications
tolerance
compositions
Prior art date
Application number
HU0302492A
Other languages
English (en)
Inventor
Tahir Ahmed
Original Assignee
Baker Norton Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26803748&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302492(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baker Norton Pharmaceuticals, Inc. filed Critical Baker Norton Pharmaceuticals, Inc.
Publication of HUP0302492A2 publication Critical patent/HUP0302492A2/hu
Publication of HUP0302492A3 publication Critical patent/HUP0302492A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány hörgőtágítókkal szemben kifejlődő megszokás, közelebbrőlb2-adrenerg agonistákkal szemben kifejlődő megszokás megelőzésérealkalmas eljárásra és készítményre vonatkozik. A találmány szerintieljárások és készítmények működési vizsgálatokban analitikaieszközként, továbbá az orvosi gyakorlatban terápiás eszközkénthasználhatók Ó
HU0302492A 1998-10-30 1999-10-13 Methods and compositions for the prevention of tolerance to medications HUP0302492A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10650798P 1998-10-30 1998-10-30
US09/362,540 US6235725B1 (en) 1998-10-30 1999-07-28 Methods and compositions for the prevention of tolerance to medications
PCT/US1999/024034 WO2000025723A2 (en) 1998-10-30 1999-10-13 Methods and compositions for the prevention of tolerance to medications

Publications (2)

Publication Number Publication Date
HUP0302492A2 true HUP0302492A2 (hu) 2003-11-28
HUP0302492A3 HUP0302492A3 (en) 2005-05-30

Family

ID=26803748

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302492A HUP0302492A3 (en) 1998-10-30 1999-10-13 Methods and compositions for the prevention of tolerance to medications

Country Status (25)

Country Link
US (1) US6235725B1 (hu)
EP (1) EP1124563B1 (hu)
JP (1) JP4585121B2 (hu)
CN (2) CN100352448C (hu)
AR (2) AR023911A1 (hu)
AT (1) ATE277621T1 (hu)
AU (1) AU760119B2 (hu)
BR (1) BR9915818A (hu)
CA (1) CA2348926C (hu)
CO (1) CO5160320A1 (hu)
CY (1) CY1107493T1 (hu)
CZ (1) CZ297914B6 (hu)
DE (1) DE69920734T2 (hu)
ES (1) ES2228173T3 (hu)
HK (1) HK1041596A1 (hu)
HU (1) HUP0302492A3 (hu)
IL (2) IL142865A0 (hu)
IS (1) IS2321B (hu)
NO (1) NO333194B1 (hu)
NZ (1) NZ511399A (hu)
PL (1) PL195592B1 (hu)
PT (1) PT1124563E (hu)
SK (1) SK285150B6 (hu)
TW (1) TW565451B (hu)
WO (1) WO2000025723A2 (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DZ3477A1 (hu) * 2000-10-12 2002-04-18
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
CA2516318C (en) * 2002-02-18 2011-07-19 University Of Southampton Use of glycosaminoglycans such as heparin for the treatment of respiratory disorders such as copd
EP1513502B1 (en) * 2002-02-18 2015-12-30 Ockham Biotech Limited Combination therapy for respiratory disorders
CA2516322C (en) * 2002-02-18 2013-10-15 University Of Southampton Glycosaminoglycan-dnase combination therapy
DE60318938T2 (de) 2002-03-20 2009-01-22 Mannkind Corp., Valencia Inhalationsgerät
CA2483271A1 (en) * 2002-04-25 2003-11-06 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7763280B2 (en) * 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
JP4851185B2 (ja) 2003-05-16 2012-01-11 ジェレックスインターナショナル株式会社 アレルギー症状抑制剤及び空気濾過フィルター
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
KR20160022404A (ko) 2005-09-14 2016-02-29 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
EP3281663B8 (en) 2008-06-13 2022-09-21 MannKind Corporation Breath powered dry powder inhaler for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
WO2011133687A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for inhibition of beta2-adrenergic receptor degradation
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CN104069497A (zh) * 2014-06-27 2014-10-01 东莞市凯法生物医药有限公司 一种降低药物耐受性的组合物、方法及其应用
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20190070244A1 (en) * 2017-06-30 2019-03-07 The New Zealand Institute For Plant And Food Research Limited Boysenberry compositions and methods of preparation and use thereof
CA3070571A1 (en) 2017-08-08 2019-02-14 Odette M. Shaw Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
ES2079210T3 (es) 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
CZ20011518A3 (cs) 2002-04-17
NO20012097L (no) 2001-06-15
CA2348926C (en) 2011-08-23
JP2002535245A (ja) 2002-10-22
CY1107493T1 (el) 2013-03-13
US6235725B1 (en) 2001-05-22
EP1124563B1 (en) 2004-09-29
HK1041596A1 (zh) 2002-07-12
HUP0302492A3 (en) 2005-05-30
CN100352448C (zh) 2007-12-05
CO5160320A1 (es) 2002-05-30
DE69920734T2 (de) 2005-10-06
EP1124563A4 (en) 2002-01-02
NZ511399A (en) 2004-09-24
BR9915818A (pt) 2002-06-18
IL142865A (en) 2006-07-05
IL142865A0 (en) 2002-03-10
AU760119B2 (en) 2003-05-08
CN1329496A (zh) 2002-01-02
AR023911A1 (es) 2002-09-04
IS5928A (is) 2001-04-27
ES2228173T3 (es) 2005-04-01
ATE277621T1 (de) 2004-10-15
NO20012097D0 (no) 2001-04-27
AR082913A2 (es) 2013-01-16
DE69920734D1 (de) 2004-11-04
IS2321B (is) 2007-12-15
CN1572303A (zh) 2005-02-02
CA2348926A1 (en) 2000-05-11
CZ297914B6 (cs) 2007-04-25
WO2000025723A3 (en) 2000-07-27
TW565451B (en) 2003-12-11
AU1205100A (en) 2000-05-22
SK285150B6 (sk) 2006-07-07
EP1124563A2 (en) 2001-08-22
NO333194B1 (no) 2013-04-02
SK5902001A3 (en) 2002-07-02
PL364727A1 (en) 2004-12-13
WO2000025723A2 (en) 2000-05-11
PL195592B1 (pl) 2007-10-31
JP4585121B2 (ja) 2010-11-24
PT1124563E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
HUP0302492A2 (hu) Gyógyszer megszokás megelőzésére alkalmas eljárások és készítmények
DK1303632T3 (da) Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf
HUP0300472A2 (hu) Topikális helyi érzéstelenítż alkalmazáshoz való intradermális penetrációs anyagok
RS51903B (sr) Formulacija aripiprazol kompleksa i postupak
ATE429210T1 (de) Orale flüssige zusammensetzungen
IS1847B (is) Nituroxíð sýntasa latar, notkun og aðferð til framleiðslu þeirra, ásamt lyfjasamsetningum
DE60227956D1 (de) Offene ringe enthaltendes copolymer, hydriertes offene ringe enthaltendes copolymer, verfahren zu deren herstellung und zusammensetzungen
IL137176A0 (en) Antibodies to 4dr and uses thereof
ES8504246A1 (es) Un metodo para la preparacion de las proteasas fibrinoliticamente activas
SG149000A1 (en) Gag binding proteins
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
MXPA02010149A (es) Composiciones de compuestos bioquimicos comprendidos en el metabolismo de bioenergia de las celulas y metodo de uso..
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ATE232700T1 (de) Implantatkörper
EP1111384A4 (en) METHOD FOR PREVENTING BLOOD DENATURATION AND APPROPRIATE BLOOD TEST
SE9603725D0 (sv) New teatment
IT1314879B1 (it) Procedimento di controllo dell'azionamento dell'utensile in undispositivo endodontico da fresatura, e dispositivo endodontico
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
NO20051261L (no) Morfin-6-glukuronidsalt
ATE254137T1 (de) ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
AU2002251533A1 (en) Protein involved in restoration of cytoplasmic male sterility to fertility and gene encoding the protein and gene
HUP0400262A2 (hu) Glikopeptidek, előállításuk és alkalmazásuk szklerózis multiplex kezelésében
NO20023969L (no) Konsentratblanding omfattende polymer og lösningsmiddelfritt metalloleat, og fremgangsmåte for fremstilling av denne
WO2001016355A3 (de) In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen
DE69902636T2 (de) Verfahren und werkzeuge zur kollektiven herstellung von mikroreliefs, insbesondere von mikroprismen, durch mikrobearbeitung

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DR. FEHERVARI FLORA, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU

Representative=s name: SZENTPETERI ZSOLT SZABADALMI UEGYVIVOE, S.B.G., HU

FH92 Termination of representative

Representative=s name: DR. FEHERVARI FLORA, DANUBIA SZABADALMI ES VED, HU

HC9A Change of name, address

Owner name: IVAX RESEARCH, INC., US

Free format text: FORMER OWNER(S): BAKER NORTON PHARMACEUTICALS, INC., US; IVAX LABORATORIES, INC., US

GB9A Succession in title

Owner name: DR. TAHIR AHMED, US

Free format text: FORMER OWNER(S): BAKER NORTON PHARMACEUTICALS, INC., US; IVAX LABORATORIES, INC., US; IVAX RESEARCH, INC., US

FC4A Lapse of provisional application due to refusal